Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA Approves New Treatment for Pompe Disease


SILVER SPRING, Md., Aug. 6, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Nexviazyme (avalglucosidase alfa-ngpt) for intravenous infusion to treat patients 1 year of age and older with late-onset Pompe disease.

Patients with Pompe disease have an enzyme deficiency that leads to the accumulation of a complex sugar, called glycogen, in skeletal and heart muscles, which cause muscle weakness and premature death from respiratory or heart failure. Normally, glycogen?the stored form of glucose?breaks down to release glucose into the bloodstream to be used as fuel for the cells.

"Pompe disease is a rare genetic disease that causes premature death and has a debilitating effect on people's lives," said Janet Maynard, M.D., deputy director of the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine in the FDA's Center for Drug Evaluation and Research. "Today's approval brings patients with Pompe disease another enzyme replacement therapy option for this rare disease. The FDA will continue to work with stakeholders to advance the development of additional new, effective and safe therapies for rare diseases, including Pompe disease."  

Nexviazyme, an enzyme replacement therapy, is an intravenous medication that helps reduce glycogen accumulation. The effectiveness of Nexviazyme for the treatment of Pompe disease was demonstrated in a study of 100 patients who were randomized to take Nexviazyme or another FDA-approved enzyme replacement therapy for Pompe disease. Treatment with Nexviazyme improved lung function similar to the improvement seen with the other therapy.

The most common side effects included headache, fatigue, diarrhea, nausea, joint pain (arthralgia), dizziness, muscle pain (myalgia), itching (pruritus), vomiting, difficulty breathing (dyspnea), skin redness (erythema), feeling of "pins and needles" (paresthesia) and skin welts (urticaria). Serious reactions included hypersensitivity reactions like anaphylaxis and infusion-associated reactions, including respiratory distress, chills and raised body temperature (pyrexia). Patients susceptible to fluid volume overload or with compromised cardiac or respiratory function may be at risk for serious acute cardiorespiratory failure.

The FDA granted this application Fast Track, Priority Review and Breakthrough Therapy designations. Nexviazyme also received an orphan drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases. The FDA granted the approval of Nexviazyme to Genzyme Corporation.

Media Contact: Alison Hunt, 202-308-5496
Consumer Inquiries: Email or 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

 

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 11:00
Battery Ventures, a global, technology-focused investment firm, today announced a significant investment in AdaCore, a leader in providing software development tools for safety- and security-critical systems. This strategic partnership will catalyze...

at 10:58
Courier, Express and Parcel (CEP) companies that need to increase their distribution network capacity can now access a full line of Interroll® modular, sorting and pallet conveyor systems from Ultimation Industries, an MCE company. Ultimation is one...

at 10:55
In an unprecedented move within the financial sector, Banxso, a pioneering online trading platform, has announced the launch of its innovative financial product offering consumers unparalleled flexibility with their investments. The platform is set...

at 10:54
LatentView Analytics Limited (BSE: 543398, NSE: LATENTVIEW), a global digital analytics consulting and solutions firm, today announced the Board approval on the acquisition of Decision Point, for acquisition of 70% of outstanding equity capital for a...

at 10:45
Biome Analytics, the leader in cardiovascular performance improvement solutions, is pleased to announce the launch of its latest innovation, the Biome Risk Audit. Developed to address challenges in risk reporting and documentation accuracy in...

at 10:45
The "New Frontier: Significant Advancements in Handheld Gaming PCs" report has been added to  ResearchAndMarkets.com's offering. This report delves into the product design of handheld gaming PCs and examines their potential future development. In...



News published on and distributed by: